Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7147151 | 0.92 | HTR2A (0.58) | CHRM2CHRM3ESR1HTR2ASIGMAR1 | |
| SCHEMBL7141415 | 0.90 | CHRM4 (0.54) | HTTCHRM2CHRM3ESR1HTR2A | |
| SCHEMBL7142247 | 0.89 | NPSR1 (0.56) | CHRM2CHRM3ALDH1A1ESR1HTR2A | |
| SCHEMBL7141686 | 0.84 | CHRM2 (0.61) | CHRM2CHRM3ALDH1A1SIGMAR1OPRM1 | |
| SCHEMBL7149576 | 0.83 | BCHE (0.54) | CHRM2HTR2ABCHEACHEBACE1 | |
| SCHEMBL7257312 | 0.82 | ALDH1A1 (0.56) | CHRM2CHRM3ALDH1A1SIGMAR1ACHE | |
| SCHEMBL7141075 | 0.81 | HTT (0.56) | HTTCHRM2CHRM3ALDH1A1CYP2D6 | |
| SCHEMBL9785741 | 0.81 | OPRM1 (0.57) | CHRM2CHRM3HTR2ASIGMAR1OPRM1 | |
| SCHEMBL7166030 | 0.80 | CHRM2 (0.57) | CHRM2CHRM3ALDH1A1SIGMAR1OPRM1 | |
| SCHEMBL7165839 | 0.80 | CHRM2 (0.57) | CHRM2CHRM3ALDH1A1SIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | claimed |
| EP-1296950-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS Allelix Corp. (CA) | 2003-04-02 | — | — | EP | claimed |
| WO-2001081308-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS ALLELIX CORP. (CA) | 2001-11-01 | — | — | WO | claimed |
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | disclosed |
| EP-1296950-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS Allelix Corp. (CA) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001081308-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS ALLELIX CORP. (CA) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176461-A1 | Aminopiperidines | SLC1A2, SLC6A4, SLC1A1 | HTT 315/4885CHRM2 320/4885CHRM3 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.